Please try another search
Peak Bio, Inc., a clinical-stage biopharmaceutical company, focuses on developing therapeutics for the treatment of patients with inflammatory, cancer, and rare and specialty diseases. The company’s lead product candidate is PHP-303, which is in phase 2 clinical study for the treatment of alpha-1 antitrypsin deficiency and acute respiratory distress syndrome. It also develops Trop2 PH1, an antibody-drug-conjugate for solid tumors. The company was founded in 2020 and is based in Pleasanton, California.
Name | Age | Since | Title |
---|---|---|---|
Stephen LaMond | 61 | 2022 | Interim CEO, COO, Secretary & Director |
Hoyoung Huh | 54 | - | Executive Chairman (Leave of Absence) |
David Ira Rosenberg | 50 | - | Director |
Satyajit Mitra | 49 | - | Head of Oncology & Executive Director |
James R. Neal | 67 | - | Independent Director |
Michael Friedman | - | 2023 | Independent Director |
Are you sure you want to block %USER_NAME%?
By doing so, you and %USER_NAME% will not be able to see any of each other's Investing.com's posts.
%USER_NAME% was successfully added to your Block List
Since you’ve just unblocked this person, you must wait 48 hours before renewing the block.
I feel that this comment is:
Thank You!
Your report has been sent to our moderators for review